HCV Management in Decompensated Cirrhosis: Current Therapies
|
|
- Suzan Sutton
- 6 years ago
- Views:
Transcription
1 Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University HCV Management in Decompensated Cirrhosis: Current Therapies ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 1 of 16
2 Childs Class Dose Adjustments in Cirrhosis PEG IFN alfa 2a, μg/wk PEG IFN alfa 2b, μg/kg/wk Ribavirin Daily A mg/day B No No 6 mg C No No 6 mg Childs Class Sofosbuvir Simeprevir Ledipasvir/ sofosbuvir A 4 mg 15 mg 9 mg/4 mg PTV/OMB/DSB 75/5/12.5 mg + 25 mg B 4 mg No* 9 mg/4 mg No* C 4 mg No 9 mg/4 mg No Daclatasvir 6 mg 6 mg 6 mg Persons with CTP B/C are difficult to treat and the clinical benefit is debated NS3 inhibitors are not recommended and may cause drug-induced liver injury Paritaprevir/r (part of 3D) Grazoprevir (with elbasvir) Simeprevir SOF/NS5As (LDV or DAC) combinations may be used ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 2 of 16
3 LDV/SOF + RBV: Genotype 1 and 4 with Advanced Liver Disease Week Week 12 Week 24 Week 36 LDV/SOF + RBV SVR12 LDV/SOF + RBV SVR12 SOLAR-1 Treatment naïve or experienced CPT Class B CPT Class C Post liver transplantation SOLAR-2: (greater G4 population) Treatment naïve or experienced CPT Class B CPT Class C Post liver transplantation SOLAR-1 and SOLAR-2 Charlton M, et al. Gastroenterology, 215 [epub ahead of print] Reddy RT, et al. Presented at: AASLD; November 7-11, 214; Boston, MA. Abstract 8. Manns M, et al. Presented at: EASL; April 22-26, 215; Vienna, Austria. Abstract G2. LDV/SOF + RBV: SVR12 in Genotype 1 or 4 with Decompensated Cirrhosis Comparable efficacy between SOLAR-1 and SOLAR-2 studies LDV/SOF + RBV 12 weeks LDV/SOF + RBV 24 weeks SVR12 (%) SVR12 (%) n/n = 26/ 3 CTP B 24/ 27 19/ 22 CTP C 18/ 2 SOLAR-1: GT 1 and 4 [1.2] 2 n/n = CTP B CTP C AE, adverse event; CTP, Child-Turcotte-Pugh; LDV, ledipasvir; RBV, ribavirin; SAE, serious adverse event; SOF, sofosbuvir. 1. Charlton M, et al. Gastroenterology, 215 [epub ahead of print] 2. Flamm SL, et al. Presented at: AASLD; November 7-11, 214; Boston, MA. Abstract Manns M, et al. Presented at: EASL; April 22-26, 215; Vienna, Austria. Abstract G2. 2/ 23 22/ 23 17/ 2 SOLAR-2: GT 1 [3] 13/ 18 ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 3 of 16
4 LDV/SOF + RBV: Safety in Advanced Liver Disease Pre OLT Safety Outcome, n (%) Pretransplant CPT B + C (n = 215) Grade 3/4 AE 51 (24) SAE 61 (28) Serious treatment-related AE 5 (2) AE leading to discontinuation of LDV/SOF 9 (4) > 2 patients HCC Sepsis 2 (<1) 2 (<1) Death 1 (5) Liver Transplantation 11 (5) Treatment-related serious adverse events (SAEs) mostly related to RBV No deaths or D/C attributed to treatment with study drug (LDV/SOF) Samuel D, et al. Presented at: EASL; April 22-26, 215; Vienna, Austria. Poster P774. SOLAR-1 and SOLAR-2 LDV/SOF + RBV: Change in MELD Score from Baseline to Follow-up Week 4 in CPT B or C Disease Change in MELD Score Pre/Post-Transplantation (CPT B and C; n = 136)* n = 18 * (8) -1 ** (-17) (-11) *Missing FU-4: n = 24. Manns M, et al. Presented at: EASL; April 22-26, 215; Vienna, Austria. Abstract G2. SOLAR-2 ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 4 of 16
5 Real-World Efficacy of SOF/SMV ± RBV & SOF/RBV Regimens in Cirrhosis Pts With MELD >1 HCV-Target Network: North America, Germany, Israel SOF + RBV (n = 12) SOF + SMV (n = 117) SOF + SMV + RBV (n = 34) MELD 1-15 MELD MELD >21 SVR12 (%) GT1 Naive GT 1Exp d GT 2 GT n/n = 3/ 7 31/ 4 6/ 1 8/ 14 8/ 48/ / 48/ / 26 1/ 26 37/ 67 67/ 92 19/ 28 5/ 8 7/ 1 2/ 3 / 1 6/ 6 1/ 1 Reddy RK, et al. Presented at: EASL; April 22-26, 215; Vienna, Austria. Abstract O7. HCV TARGET HCV TARGET: SAEs, Death, Liver Transplantation SOF/RBV N=88 SOF/SMV N=114 SOF/SMV/ RBV N=32 Total N=234 Total patients with SAEs N (%) 27 (31) 8 (7) 9 (26) 44 (17) Hepatic decompensation* 1 (11) 2 (2) 4 (12) 16 (6) Infections 2 (2) 1 (3) 1 (4) Death 2 (2) 1 (3) 3 (1) Unspecified 1 (3) 1 (.4) Hepatic Failure 1 (1) () 1 (.4) Shock 1 (1) 1 (.4) Underwent OLT on treatment 4 (5) 3 (3) 5 (16) 12 (5) *Hepatic encephalopathy, variceal bleeding, hepatic failure, hepatic hydrothorax, bacterial peritonitis Reddy RK, et al. Presented at: EASL; April 22-26, 215; Vienna, Austria. Abstract O7. ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 5 of 16
6 ALLY-1: SOF + DCV + RBV for 12 Weeks in Patients With Genotype 1 HCV and Cirrhosis SVR12, % Treatment naïve or treatment experienced adults with any HCV genotype DAA failures allowed, except NS5A a 1b Genotype Child-Pugh score: A, B, or C MELD scores 8-4 Hepatocellular carcinoma allowed Poordad F, et al. Presented at: EASL; April 22-26, 215; Vienna, Austria. Abstract LO8. SVR12, % All Genotypes /12 3/32 9/16 A B C Child-Pugh class ALLY-1 8 SVR12 by Baseline Disease Severity SVR12 by Child-Pugh Class Advanced cirrhosis cohort, all genotypes SVR12, % A B C Child-Pugh class No Yes No Yes > <2.8 <1.71.7>2.3 <2. 2. >3. to 3.5 to 2.3 to 3. HE = hepatic encephalopathy Ascites HE Albumin, g/dl INR T bili, mg/dl 12 ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 6 of 16
7 Treatment of Decompensated HCV Cirrhosis in Patients with Diverse Genotypes: 12 weeks Sofosbuvir and NS5A inhibitors With/Without Ribavirin Non-randomized observational cohort study of National Health Service of England (N = 467) Patients received 12 weeks SOF + LDV or DCV ± RBV at treating MD discretion (non-randomized) 12-wk SOF + LDV + RBV 12-wk SOF + LDV 12-wk SOF + DCV + RBV 12-wk SOF + DCV P< SVR12, % (ITT) 2 N = All GT1 GT3 Other GT DCV, daclatasvir; GT, genotype; HCV, hepatitis C virus; ITT, intent to treat. Foster GR, et al. Presented at: EASL; April 22-26, 215; Vienna, Austria. Abstract O2. European Compassionate Use Program (CUP): SOF + DCV ± RBV for 24 Weeks 8 24-wk DCV + SOF wk DCV + SOF + RBV All patients SVR12, % / 19/ 58/ 24/ 21/ 45/ 1/1 1/1 2/2 n/n = A B C CP Score Treatment naive or treatment experienced CP Category: 57% CP A; 36% CP B; 6% CP C MELD Scores: >5% had MELD Scores 9 and <15 DCV dose determined by country; inclusion of RBV based on physician discretion Welzel TM, et al. Presented at: EASL; April 22-26, 215; Vienna, Austria. Abstract P772. ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 7 of 16
8 Study Design ASTRAL-4 Childs B Cirrhosis Wk Wk 12 Wk 24 Wk 36 n=75 SOF/VEL SVR12 n=75 SOF/VEL + RBV SVR12 n=75 SOF/VEL SVR12 Open-label, randomized (1:1:1) US study GT 1-6 treatment-naïve or -experienced patients with CPT B cirrhosis Eligibility criteria: CrCL >5 ml/min, platelets >3, x 1 3 /μl; no HCC or liver transplant Weight-based RBV dosing ( or 12 mg/day) Results: SVR12 in GT 1 Patients ASTRAL SVR relapse 2 death 1 LTFU 1 relapse 2 deaths 3 relapse 3 LTFU 6/68 SOF/VEL 65/68 SOF/VEL+ RBV 65/71 SOF/VEL 12 week 12 week 24 week ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 8 of 16
9 Results: SVR12 in GT 3 Patients ASTRAL SVR relapses 1 death 1 breakthrough 1 relapse 5 1 breakthrough 4 relapse 1 death 7/14 SOF/VEL 11/13 SOF/VEL+ RBV 6/12 SOF/VEL 12 week 12 week 24 week ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 9 of 16
10 Solutions for patients with decompensated cirrhosis due hepatitis C 1. Observe closely for complications 2. Treat hepatitis C, observe for clinical improvement 3. Treat hepatitis C while listing for transplant 4. List for transplant, treat post OLT If we treat, will they improve clinically? ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 1 of 16
11 Post liver transplant treatment of HCV infection Post transplant Drug interactions: DAAs as Culprits Medication Cyclosporine Tacrolimus Sirolimus Everolimus Cmax AUC Cmax AUC Cmax AUC Cmax AUC Ribavirin Ledipasvir ND ND ND ND ND ND Sofosbuvir 27% 9% ND ND ND ND Simeprevir 16% 19% 24% 17% ND ND ND ND Daclatasvir 4% 3% 5% ND ND ND ND 3D Regimen 1% 482% 299% 5613% Expected increase in both Cmax and AUC. Expected increase in both Cmax and AUC. HCV infection inhibits cytochrome P45 through direct and indirect mechanisms. SVR leads to lower CNI levels and risk of ACR. Dick TB, et al. Hepatology [Epub ahead of print] ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 11 of 16
12 Post transplant Drug interactions: DAAs as Victims (CYA and TAC affect DAA metabolism or transport) Medication Daclatasvir Ledipasvir Sofosbuvir Simeprevir Cmax AUC Cmax AUC Cmax AUC Cmax AUC Cyclosporine 4% 4% ND ND 154% 353% 374% 481% Tacrolimus 7% 5% ND ND 3% 13% 79% 85% Dick TB, et al. Hepatology [Epub ahead of print] SOLAR-1: SVR12 Rates in OLT Patients Receiving LDV/SOF + RBV wks LDV/SOF + RBV 24 wks LDV/SOF + RBV SVR12 (%) n/n = 53/ 55 55/ 56 25/ 26 24/ 25 22/ 26 15/ 18 F-F3 CPT A CPT B CPT C 3/ 5 2/ 3 In the 24-week arm, 8 patients with CPT B and 1 patient with CPT C have not reached the follow-up week 12 visit MELD scores improved from baseline through follow-up Week 4 in 15/48 patients with CPT A and 8/41 patients with CPT B disease Reddy RT, et al. Hepatology. 214;6(suppl): Abstract 8. ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 12 of 16
13 Solar-2: LDV/SOF + RBV: SVR12* in Genotype 1 or 4 Comparable efficacy between 12 and 24 week durations LDV/SOF + RBV 12 weeks LDV/SOF + RBV 24 weeks SVR12 (%) SVR12 (%) n/n = 72/ 75 57/ 58 F-F3, CPT A 57/ 65 54/ 61 CTP B&C 2 n/n = 1/ 11 7/7 F-F3, CPT A 4/7 6/7 CTP B&C SOLAR-2: GT 1. Manns M, et al. Presented at: EASL; April 22-26, 215; Vienna, Austria. Abstract G2. SOLAR-2: GT 4 SOLAR-1: LDV/SOF + RBV in Post Transplant Change in MELD Score Change from Baseline to Follow-Up Week 4 CTP A Patients (n=48) CTP B Patients (n=41) 12 Wk (n=23) 24 Wk (n=25) 12 Wk (n=21) 24 Wk (n=2) n=9 n=4 n=4 n= Reddy, AASLD, 214, Oral #8 (-11) -4-6 Missing FU-4: n=3 CTP A 12 wk; n=5 CTP B 12 wk; n=5 CTP B 24 wk -8 ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 13 of 16
14 Ally-1 : SOF +DCV+RBV 6 Post OLT SVR12 by HCV Genotype N = SVR12, % /53 3/31 9/1 Overall 1a 1b 1/11 1/1 3 6 Genotype Poordad F, et al. Presented at: EASL; April 22-26, 215; Vienna, Austria. Abstract LO8. SVR 12, % SOF +DCV+RBV 6 Post OLT Interim SVR12 Results Post-transplant Cohort DCV + SOF DCV + SOF + RBV All patients Relapse, n=1 Deaths, n= GT 1 GT 3 All GT HCV genotype NS5A sequencing (population-based) in relapse patient identified Y93S RAV ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 14 of 16
15 CORAL-1: GT1 Patients After Liver Transplantation (F-F2) PTV/OMB/DSB + RBV (n=34) SVR12 Day Week 24 To Week 72 PTV/OMB/DSB: co-formulated paritaprevir/r/ombitasvir, 15 mg/ mg/25 mg QD; dasabuvir, 25 mg BID RBV: dosing was managed at the discretion of the investigator and closely monitored per protocol Tacrolimus.5 mg q 1-2 weeks, Cyclosporin reduced to 2% of daily dose Kwo PY, et al. N Engl J Med. 214;371(25): CORAL-1: SVR Rates in GT1 Liver Transplant Patients % 9% 8% 7% 6% 5% 4% 3% 2% 1% % % 97% 97% 97% EOTR SVR4 SVR12 SVR24 No patient had breakthrough One patient had a relapse (post-treatment day 3) At the time of relapse, this patient had R155K in NS3 protease, M28T+Q3R in NS5A, and G554S+G557R in NS5B, none of which were present at baseline Study now including F3-F4, 12 week duration ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 15 of 16
16 HCV-TARGET Post Transplant HCV RNA Outcomes for SOF+SMV±RBV: Genotype 1 interim analysis 9% 87% 95% 88% 96% 88% 95% 9% 8% 8 6 SVR % /14 52/6 42/44 51/58 27/28 59/67 35/37 19/21 8/1 Overall Tx Experienced Yes No Genotype 1a 1b Cirrhotic Yes No MELD < 1 1 Summary Patients with decompensated cirrhosis may be treated successfully across all genotypes SVR rates are good, lower than compensated cirrhosis SOF/VEL/RBV, SOF/LDV ± RBV weeks, SOF/DCV ± RBV weeks Carefully consider who to treat in transplant setting to avoid MELD purgatory Post Liver Transplant: Do your drug interactions No graft should fail due to recurrent HCV across all genotypes 12 weeks of SOF/LDV/RBV or SOF/DCV/RBV 24 weeks of SOF/LDV or SOF/DCV 24 weeks of PTV/OMB/DSV±RBV SOF/VEL and GRZ/ELB will likely be effective, data pending ACG 216 Southern Hepatitis School Copyright 216 American College of Gastroenterology Page 16 of 16
Hepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationHepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of
Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology www.livermd.org HCV in advanced disease In principle
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationTreating HCV After Liver Transplantation: What are the Treatment Options?
4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationTreatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Treatment of Hepatitis C Recurrence after Liver Transplantation Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Agenda 1. Introduction 2. Treatment options for hepatitis C recurrence after transplantation
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More informationHCV Treatment in 2016
HCV Treatment in 2016 Hugo E. Vargas, MD Professor of Medicine Mayo College of Medicine Medical Director, Clinical Trials Office Vice Chair, Department of Research Educational Goals Caveats: Cannot cover
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationManaging HCV in Liver Transplant: Optimizing Success with New DAA Regimens
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationHCV Therapy in Liver Transplant Candidate
PHC 216 HCV Therapy in Liver Professor Didier SAMUEL Transplant Candidate Dr Audrey COILLY Centre Hépato-Biliaire, Inserm 1193 Treat before orrearch afuniter? University Paris Sud A Villejuif u d r e yfrance
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationManagement of HCV in Decompensated Liver Disease
Management of HCV in Decompensated Liver Disease Michael P. Manns Hannover Medical School (MHH) Department of Gastroenterology, Hepatology and Endocrinology Helmholtz Center for Infection Research (HZI),
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationSOLAR-1 (Cohorts A and B)
Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; [Epub ahead of print]
More informationVIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015
VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationDAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo
DAAs in the era of decompensated liver disease Piero L. Almasio University of Palermo piero.almasio@unipa.it HCV therapy in the era of interferon based therapy Priority Compensated cirrhosis Decompensated
More informationSOLAR-1 (Cohorts A and B)
Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; 149:649-59. Ledipasvir-Sofosbuvir
More informationWhat Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationA One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
More informationNext generation DAAs: Combining efficacy and safety profile. Jiannis Vlachogiannakos
Next generation DAAs: Combining efficacy and safety profile. Jiannis Vlachogiannakos Associate Professor of Gastroenterology, Academic Department of Gastroenterology, National and Kapodistrian University
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationHCV TREATMENT PRE- AND POST TRANSPLANTATION
HCV TREATMENT PRE- AND POST TRANSPLANTATION Mitchell L. Shiffman, MD, FACG Medical Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA IVer Liver Institute
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationHepatitis C Difficult to Treat. Population. Disclosures
Hepatitis C Difficult to Treat Populations Paul Y Kwo MD Professor of Medicine Director of Hepatology Stanford University School of Medicine 75 Welch Road #21 Palo Alto, CA 9434 Disclosures Advisory Board
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationRecurrent HCV after a Pre-LTx Course of SOF/DAC:
Recurrent HCV after a Pre-LTx Course of SOF/DAC: Didier Samuel, Teresa Antonini Centre Hépato-Biliaire, Inserm Paris Sud Research Unit 1193 Hôpital Paul Brousse, Villejuif, France 3 rd Optimize Workshop,
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationCCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015
CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015 CCO Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases, November
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationHCV: Current SOTA of Management of Treatment Experienced Patients
HCV: Current SOTA of Management of Treatment Experienced Patients Robert G Gish MD Professor Consultant Stanford University Executive Committee: National Viral Hepatitis Roundtable Founding Member: CEVHAP
More informationTreatment of recurent hepatitis infection after liver transplantation
Paris PHC, 11 janvier 2016 Treatment of recurent hepatitis infection after liver transplantation Georges-Philippe Pageaux CHU Saint Eloi, Digestive department gp-pageaux@chu-montpellier.fr Disclosures
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationManagement of HCV Tawesak Tanwandee
Management of HCV 2016 Tawesak Tanwandee Topics Burden of HCV in our countries Natural history and unmet need for HCV treatment Current treatment as for 2016 Conclusion Evolution from HCV infection to
More informationAddressing Unmet Medical Needs in HCV Genotype 3
Addressing Unmet Medical Needs in HCV Genotype 3 Karen Doucette, MD, MSc (Epi), FRCPC Associate Professor, Division of Infectious Diseases, Department of Medicine University of Alberta Objectives Identify
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationPatients with compensated cirrhosis: how to treat and follow-up
Patients with compensated cirrhosis: how to treat and follow-up Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Leber- und Studienzentrum
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationFailure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016
Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,
More informationMulticenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment
ORIGINAL ARTICLE September-October, Vol. 17 No. 5, 2018: 815-821 815 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian
More informationHEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA
NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationPatients with Cirrhosis: Managing the HCV Peri-Transplant Patient
Patients with Cirrhosis: Managing the HCV Peri-Transplant Patient Fred Poordad, MD Professor of Medicine University of Texas Health Science Center VP, Academic and Clinical Affairs The Texas Liver Institute
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationThe ASTRAL Program Abstracts LB-2, LB-12, 205, 209
The ASTRAL Program Abstracts LB-2, LB-12, 5, 9 The ASTRAL Program FDC 1. 2. 3. 4. 5. SOF Nucleotide polymerase inhibitor VEL NS5A inhibitor ASTRAL1 GT1, 2, 4 6 ASTRAL2 GT2 Jacobson IM, et al. N Engl J
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationDuncan Webster, BSc, BA, MA, MD, FRCPC
Moderator Duncan Webster, BSc, BA, MA, MD, FRCPC Internist, Infectious Disease Physician, Department of Medicine Medical Microbiologist, Department of Laboratory Medicine, Saint John Regional Hospital
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationWonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited
Wonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited Harald Hofer Department of Internal Medicine III Division of Gastroenterology and Hepatology Medical
More informationActivity Overview. Target Audience
Activity Overview In this activity, Dr. Kwo discusses treatment approaches for the few populations in which HCV remains difficult to treat, including patients who have not responded to direct acting antiviral
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationGestione del paziente nel pre e post trapianto di fegato
Gestione del paziente nel pre e post trapianto di fegato Maria Rosaria Piras SSD SSD Coordinamento Trapianto di Fegato Azienda Ospedaliera Brotzu Cagliari HCV Infection and Liver Transplantation HCV infection
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationHepatitis C: New Therapies in
Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and
More informationRapid Response from San Francisco: The Latest in the HCV Treatment Revolution
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationNew Hepatitis C Antivirals
New Hepatitis C Antivirals Kris Stewart, BSP, MD, FRCPC Drug Therapy Conference College of Medicine, University of Saskatchewan September 23, 2016 Disclosures I have received research and program support
More informationNorah Terrault, M.D. Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah Terrault, M.D. Grants/Research Support AbbVie, Gilead, BMS,
More information